Home / 2020 / October / 22

Daily Archives: October 22, 2020

II-VI Incorporated to Webcast FY 2021 First-Quarter Conference Call

PITTSBURGH, Oct. 22, 2020 (GLOBE NEWSWIRE) — II-VI Incorporated (Nasdaq: IIVI), a global leader in engineered materials and optoelectronic components, announced today that the Company will hold a live webcast and conference call on Thursday, November 5, 2020, at 9:00 a.m. EST. The webcast and call will be hosted by Dr. Vincent D. (Chuck) Mattera, Jr., Chief Executive Officer, Mary Jane Raymond, Chief Financial Officer, and Giovanni Barbarossa, Chief Strategy Officer and Compound Semiconductors President.

The first-quarter results will be released before the market opens on Thursday, November 5, 2020, and will be posted on the Company’s website at www.ii-vi.com/investor-relations.

Webcast URL:

Individuals wishing to participate in the webcast can access the event at the Company’s website by visiting www.ii-vi.com or via https://tinyurl.com/IIVIQ1FY21Earnings.

To join the call and replay:

If you wish to participate in the call, please dial (877) 316-5288 for U.S. calls and (734) 385-4977 for international calls. When you call, please enter ID number 4349251 and provide your name and company affiliation.

The call will be recorded, and a replay will be available to interested parties who are unable to attend the live event. This service will be available up to 11:59 p.m. EST on Monday, November 9, 2020, by dialing (855) 859-2056 for U.S. calls and (404) 537-3406 for international calls and entering the ID number 4349251.

About II-VI Incorporated

II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in communications, materials processing, aerospace & defense, semiconductor capital equipment, life sciences, consumer electronics, and automotive markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to support our customers. For more information, please visit us at www.ii-vi.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to future events and expectations that are based on certain assumptions and contingencies. The forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures.

The Company believes that all forward-looking statements made by it in this press release have a reasonable basis, but there can be no assurance that management’s expectations, beliefs, or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and global economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include but are not limited to: (i) the failure of any one or more of the assumptions stated above to prove to be correct; (ii) the risks relating to forward-looking statements and other “Risk Factors” discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020; (iii) the purchasing patterns of customers and end users; (iv) the timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the Company’s ability to assimilate recently acquired businesses, and risks, costs, and uncertainties associated with such acquisitions; (vii) the Company’s ability to devise and execute strategies to respond to market conditions; and/or (viii) the risks of business and economic disruption related to the currently ongoing COVID-19 outbreak and any other worldwide health epidemics and outbreaks that may arise. The Company disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or developments, or otherwise.

CONTACT: Mary Jane Raymond
Chief Financial Officer

Philips showcases integrated radiation oncology solutions to streamline diagnosis and treatment at ASTRO 2020

October 22, 2020

Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management [1] can reduce the time from patient referral to the start of treatment by up to half

Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest advances in radiation oncology at the American Society for Radiation Oncology (ASTRO) annual meeting (October 24-28). During the virtual event, Philips will showcase its comprehensive portfolio of integrated radiation oncology systems and AI‐powered software that helps radiation oncologists manage complexity and boost efficiencies to accelerate the time from patient referral to treatment.

As diagnostic and treatment workloads expand in both volume and complexity, radiation therapy departments are under mounting pressure to provide accurate treatment, while minimizing wait times for patients. Today, the radiation oncology planning process can be labor-intensive, with frequent handovers, long wait times and lags in data transfers between systems. By optimizing workflows, standardizing processes, and providing easy access to relevant patient information, Philips supports care teams by integrating clinical workflows, reducing wait times and increasing confidence in decision-making.​

“Healthcare providers are rethinking the way they organize care in order to support a streamlined, end-to-end exchange of data, which can help them achieve a faster workflow, address capability gaps and reduce costs,” said Ardie Ermers, Vice President and General Manager Radiation Oncology at Philips. “With our broad portfolio of oncology technologies and solutions, Philips is in a unique position to help providers across the end-to-end patient pathway, optimizing workflows and generating insights from integrated diagnostics, aiming for clear care pathways and predictable outcomes for every patient.”

An integrated solution supported by consultancy services
IntelliSpace Radiation Oncology [1] enables radiotherapy departments to achieve operational excellence and accelerate the time from referral of the patient to the start of their treatment. By integrating the analytics and on-site change management features of Philips’ Practice Management solution [1], radiotherapy departments can identify and act on data-driven insights to address performance gaps, monitor progress and drive sustainable change.

The South West Wales Cancer Centre (SWWCC) in the UK is among the first partner sites that have deployed the solution. “This new intelligent patient management orchestrator helps our patients by improving their experience by decreasing their time to treatment and it will help us as clinicians to consistently treat every patient to the highest quality levels,” said Dr. Russell Banner, Clinical Oncologist, and Radiotherapy Lead at SWWCC. “Our 14-step breast pathway had a referral-to-first treatment interval of 32 days initially. With full implementation of IntelliSpace Radiation Oncology and the Practice Management consultants, we think it is achievable to bring this down to just 14 days.”

Advanced Imaging and treatment planning tools
At ASTRO and beyond on its virtual radiation oncology experience website, Philips will present its dedicated radiation oncology line-up, including the Big Bore RT scanning and simulation platform (Big Bore RT) and the comprehensive MR simulation platform (Ingenia MR-RT).

Philips continues to advance its leading MR-only radiotherapy portfolio, receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AI-based MRCAT Brain application earlier this year. MRCAT reduces the organization and coordination of scans involved in MR-CT registration, saving the patient from undergoing another imaging procedure. MRCAT scans are now accelerated by Compressed Sense, a technology that speeds up scans by up to 50% [2], further helping to improve patient comfort.

​Advanced imaging capabilities tailored for MR in Radiotherapy from Philips being highlighted for ASTRO include functional imaging using DWI XD TSE with reduced distortion [3], metal artifact reduction with OMAR XD, and motion management with 3D Vane XD, which supports imaging of the abdomen without the need for the patient to hold their breath.

As the company further consolidates its radiation oncology IT platform, Philips is also showcasing its next generation of personalized IMRT and VMAT Therapy Planning System (Pinnacle Evolution) which improves the quality, consistency and efficiency of the therapy planning process.

End-to-end oncology care
With its broad portfolio of oncology-related technologies and solutions that span the end-to-end patient care-path, Philips is in a unique position to help oncology care providers to connect the disparate pathway processes and workflows to improve the efficiency, robustness and quality of oncology care. More information on Philips’ oncology portfolio is available here.

[1] Not available for sale in all markets.
[2] Compared to Philips scans without Compressed SENSE.
[3] Compared to EPI diffusion DWI.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com
Twitter: @kathyoreilly

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com
Twitter: mark_groves

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


Trip.com Group’s “LIVE for Trip” month-long campaign to further boost travel recovery

Travel On: LIVE for Trip

Travel On: LIVE for Trip official campaign image

SINGAPORE, Oct. 22, 2020 (GLOBE NEWSWIRE) — From 10 October to 11 November 2020, leading online travel services provider Trip.com Group is launching “LIVE for Trip” as a part of its Travel On initiative to bolster the recovery of the global travel industry and coincide with the company’s 21st anniversary.

The LIVE for Trip series will feature livestreaming events from leading industry representatives and KOLs who will host travel product shows and offer over 150 million USD in travel discounts and giveaways on exciting new travel products.

Every day from 10 October to 11 November, Trip.com Group platforms will host livestreams focused on different travel products and destinations. Trip.com Group regular BOSS live and Trip.com LIVE broadcasts will be joined by airline, hotel, vacation, destination and store exploration programs that showcase the newest travel packages and products on offer. Over 2,500 products tailored for the post-COVID traveler will be shared with customers, featuring over 100 hotel and airline brands, including Inter Continental, Accor, Hyatt, Shimao, Shangri-La and more.

LIVE for Trip will launch over 150 million USD in discounts for customers and funds for industry partners, helping to build on the hundreds of millions of dollars in financial assistance already invested into the industry by Trip.com Group as part of the Travel On initiative.

On 28 October, Trip.com Group platforms will host a marathon livestream broadcast with a primetime BOSS live show in Chengdu, China, a key event marking the 21st anniversary of Trip.com Group. The following day, 29 October, Trip.com Group is holding its Global Partner Summit in Chengdu, a platform to connect our industry partners, share the latest on the industry and promote the revitalization of travel.

On 29 October, Trip.com LIVE shows featuring top tourism KOLs and industry representatives will be hosted in Hong Kong, Japan and Singapore, boosting local markets. Regional travelers will have the choice of incredible pre-sales products that come with flexibooking options and health and safety guarantees, giving customers the confidence they need to travel on.

“Cherished memories of our previous trips have given us strength throughout this difficult time, and now, as travel is on track for recovery, we’re working with our partners to give users the confidence, inspiration and freedom to travel on,” said Trip.com Group’s co-founder and executive chairman James Liang.

“Travel is such an important force for good. It’s what brings us together, and breaks down barriers between us, and what the world needs most right now is the freedom to travel on safely,” said Trip.com Group CEO Jane Sun. “With innovation and industry unity there are amazing deals and exciting new products on offer, that moment is now. There’s never been a better time to start planning that next trip, and to travel on.”

Throughout this year Trip.com Group has employed innovative solutions to meet the challenges presented by COVID-19 and push forward the travel recovery. The Travel On: LIVE for Trip campaign embodies a pioneering celebratory spirit and utilizes innovative livestreaming channels to share thousands of new products tailored for today’s travelers.

About Trip.com Group:
Trip.com Group is a leading one-stop travel service provider comprising of Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group enables local partners and travelers around the world to make informed and cost-effective bookings for travel products and services, through the aggregation of comprehensive travel-related information and resources, and an advanced transaction platform consisting of mobile apps, Internet websites and 24/7 customer service centers. Founded in 1999 and listed on NASDAQ in 2003, Trip.com Group has become one of the best-known travel brands in the world, with the mission of ‘making every trip the perfect trip’.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/47aa4456-b563-4cd8-8511-adfbb310b4d9

For additional information, visit Trip.com Group Newsroom 
Media Relations Contact:
Trip.com Group PR 
Tel: (+86) 21 3406 4880 ext 196455

WillScot Mobile Mini Holdings to Announce Third Quarter 2020 Results on November 5, 2020

PHOENIX, Oct. 21, 2020 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corporation (Nasdaq: WSC) today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020 after the markets close.

Chief Executive Officer, Brad Soultz, President and Chief Operating Officer, Kelly Williams and Chief Financial Officer, Tim Boswell will host a conference call and webcast on Friday, November 6, 2020 at 10:00 a.m. EST to discuss the results.

The live call can be accessed by dialing (855) 312-9420 (US/Canada toll-free) or (210) 874-7774 (International). A live webcast will also be accessible via the “Events & Presentations” section of the company’s website www.willscotmobilemini.com. An archived version of the webcast will be available for 60 days following the call.

About WillScot Mobile Mini Holdings

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Based in Phoenix, Arizona, WillScot Mobile Mini Holdings is a North American leader in modular space and portable storage solutions.  It was formed in 2020 upon the merger of leaders in the modular space and portable storage markets.  Together the WillScot and Mobile Mini brands operate approximately 275 locations across the United States, Canada, Mexico, and the United Kingdom with a combined fleet of over 350,000 portable offices and storage containers.  They lease turnkey office space and storage solutions for temporary applications across a diverse customer base in the commercial and industrial construction, retail, education, health care, government, transportation, security and energy sectors.  They create value by enabling customers to add space efficiently and cost-effectively – when the solution is perfect, productivity is all the customer sees.

Additional Information and Where to Find It

Additional information can be found on the company’s website at www.willscotmobilemini.com

Contact Information

Investor Inquiries:

Mark Barbalato

Media Inquiries:

Scott Junk

Align Technology Announces Invisalign® G8 With New Smartforce® Aligner Activation Features

Latest evolution in SmartForce innovation improves treatment predictability for frequently treated case types

SAN JOSE, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) — Align Technology, Inc. (NASDAQ: ALGN) today announced the introduction of Invisalign G8 with SmartForce Aligner Activation, the latest of the company’s biomechanics innovations. Invisalign G8 with SmartForce Aligner Activation is informed by the company’s foundational biomechanics for clear aligners and its database of more than 9 million Invisalign patients to optimize tooth movements and further improve predictability for frequently treated crowding, crossbite, and deep bite cases.

“Our innovations are based on fundamental biomechanics, biomaterials science, and the orthodontic knowledge and experience gained from the more than 9 million Invisalign cases treated by Invisalign doctors – which help us define the optimal approach to specific tooth movements and case types,” said Raj Pudipeddi, Align senior vice president, chief innovation, product and marketing officer. “Invisalign G8 with new SmartForce Aligner Activation integrates optimal forces for correction in these frequently treated case types. Alongside our SmartTrack material and SmartStage technology, these latest innovations further improve treatment planning efficiency and predictability so that doctors can be even more confident in delivering great clinical outcomes.”

With SmartForce Aligner Activation, select areas of the aligner surface are specifically contoured to apply optimal forces to the tooth surfaces to control the location, direction and intensity of the force to produce the desired outcome and minimize unwanted movement. Specific, strategic contact areas between the aligner and the tooth are created by SmartForce Aligner Activation and work in concert with SmartForce features for even greater control of the force systems.

“Analysis of the tooth movements in the millions of cases shows us that certain tooth movements in treated case types require additional activation to achieve the desired tooth movement,” said Dr. Mitra Derakhshan, Align vice president, global clinical. “The additional activation is now automatically determined by the software and fabricated into the aligner as SmartForce Aligner Activation, thereby reducing doctors’ inclination to over correct certain movements in their treatment plans.”

Invisalign G8 with new SmartForce Aligner Activation ensures sufficient and consistent activation in every aligner stage to help doctors get more of the desired movements from every aligner in the treatment of crowding, crossbite, and deep bite.

  • For crowding and crossbite cases:
    – Smart Force Aligner Activation aids in posterior arch expansion by working synergistically with New Optimized Expansion Support attachments or Optimized Expansion Support and Rotation attachments to reduce the potential for buccal crown tipping during posterior arch expansion.
  • For deep bite cases:
    – SmartForce Aligner Activation supports anterior intrusion with improvements in the treatment plan set-ups to level the Curve of Spee and demonstrates up to 2x improvement in predictability of incisor intrusion.

In addition, with Invisalign G8, doctors can now select automatic placement of Precision Bite Ramps during the prescription process. Data demonstrates that Precision Bite Ramps improve lower intrusion in deep bite cases.

“Being one of the first doctors to use Invisalign G8 has been a fantastic experience. The G8 features along with SmartForce Aligner Activation enable better control and outcome of cases of patients with deep bite or for those who need a significant amount of expansion,” said Dr. Nelly Sanseverino, an orthodontist and Invisalign G8 limited market release/pilot doctor practicing in Sao Paolo, Brazil.

Invisalign G8 will be available globally on all Invisalign products in the first quarter of 2021.

About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, iTero® intraoral scanners and services, and CAD/CAM software. Align has helped treat over 9 million patients with the Invisalign system and is driving the evolution in digital dentistry with the iTero intraoral scanner and exocad® CAD/CAM software − modernizing today’s practices by enabling enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Align Technology Zeno Group
Madelyn Homick Sarah Johnson
(408) 470-1180 (828) 551-4201
mhomick@aligntech.com sarah.johnson@zenogroup.com

France, Spain Become Latest Nations to Have More Than 1 Million COVID-19 Cases

The number of nations with more than 1 million confirmed COVID-19 cases has risen to seven.

Spain and France are the latest nations to reach the unfortunate mark, according to data compiled by the Johns Hopkins University Coronavirus Resource Center. The United States tops the list with more than 8.3 million total cases, followed by India (7.6 million), Brazil (5.3 million), Russia (1.4 million) and Argentina, which has 1,037,325. Spain is in sixth place with 1,005,325 cases, followed by France with 1,000,369.

Spain and France are also the first nations in Western Europe to record more than 1 million COVID-19 infections.

Scores of researchers around the world are racing to develop a safe and effective vaccine against COVID-19, which has killed more than 1.1 million people around the globe and sickened more than 41.1 million.

Brazil’s health authority Anvisa said Wednesday that a volunteer in a late-stage clinical trial of a vaccine developed by British-Swedish pharmaceutical giant AstraZeneca had died but gave no further details about the circumstances.

The volunteer was one of the 8,000 who either received the actual vaccine or a false drug known as a placebo. Because the testing has not been suspended, sources say the volunteer was likely a part of the control group that received the placebo.

The AstraZeneca vaccine, developed in cooperation with Britain’s University of Oxford, is being tested in large-scale Phase 2 and Phase 3 trials in several nations, including the United States, Britain, South Africa and India. The drug maker temporarily put the trial on hold last month after a volunteer in Britain was diagnosed with a form of spinal inflammation after receiving a second dose of the vaccine.

The trial has since resumed in Britain, Brazil, India and South Africa but remains on hold in the United States.

The U.S. Centers for Disease Control and Prevention has revised its definition about “close contact” with a person infected with COVID-19.

The agency had previously determined that close contact was spending 15 consecutive minutes within 2 meters of an infected individual. The revised changes announced Wednesday now defines a close contact as someone who spent a total of 15 minutes accumulated over a 24-hour period.

The change by the CDC was prompted by a report of a prison officer in the northeastern U.S. state of Vermont who became infected with COVID-19 after more than 20 brief interactions with inmates who later tested positive for the virus. The brief visits added up to about 17 total minutes of exposure.


Britain to Deliberately Infect Volunteers With Coronavirus

LONDON – Healthy volunteers will be deliberately infected with the coronavirus to try to speed up the development of a vaccine, under plans announced by the British government this week.

The trial will involve healthy volunteers ages 18 to 30.

Most coronavirus vaccine trials involve giving volunteers the potential vaccine or a placebo and then waiting until enough of them have been exposed to the virus through their everyday lives. That can take months or years.

Britain announced this week it plans to begin the so-called “human challenge” trials in May 2021 to speed up the development of vaccines.

Several young people have already volunteered, among them Danica Marcos, 22, a recent university graduate from London.

“So many people [are] struggling right now. I want this pandemic to be over,” Marcos told The Associated Press. “Every day that goes on, more cases are going on, more people are dying. And if this vaccine trial could mean that this period of trauma for the whole world will be over sooner, I want to help. I want to be a part of that.”

Alastair Fraser-Urqhart, 18, from Stoke-on-Trent said he wanted to contribute to a vaccine.

“Personally, I can’t let this opportunity to do something, to really do something, pass me by when I’m at such low risk than other people,” he said.

The British government plans to invest over $43.4 million in the challenge trial. The World Health Organization said it could be significant.

“There is a very long history of this for development of a number of vaccines that has been part of what has gone on with, say, the development of the cholera vaccines and the typhoid vaccines,” said Margaret Harris, a spokeswoman for WHO.

Harris also expressed some concerns.

“What is critical is that if people are considering this, it must be overseen by an ethics committee, and the volunteers must have full consent, and they must select the volunteers in order to minimize their risk. Because you will be challenging people with a virus that we do not have a treatment for,” Harris said.

“So, you must ensure that everybody involved understands exactly what is at stake, must be selected to minimize the risk. The volunteer and you must ensure that informed consent is rigorous, that they really do understand all the risks.”

Infections, hospitalizations and deaths from the new coronavirus are rising sharply in many countries around the world. A vaccine remains the best hope of any return to some kind of normality, said Dr. Sterghios Moschos, a microbiologist at the University of Northumbria, who spoke to VOA in a recent interview.

“At this point in time, we don’t have a way of stopping transmission,” Moschos said. “And we don’t even have the financial capacity to give multiple antibody treatments, steroids, et cetera, like Donald Trump received, to everybody in the population that needs treatment. The cost is quite large for these kinds of treatments. We don’t have a vaccine. And therefore, as a result, we need to contain the spread of this virus. Not just manage it, contain it.”

The initial aim of the British research team?will be to discover the smallest amount of virus it takes to cause a COVID-19 infection, using controlled doses of the virus. If approved by regulators and an ethics committee, it is hoped the full challenge trial could begin in May 2021.